{Reference Type}: Journal Article
{Title}: Congenital hepatoblastoma: Expanding knowledge, improving outcomes.
{Author}: Gigola F;Morini F;Libro G;Morabito A;Grimaldi C;
{Journal}: Pediatr Blood Cancer
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 2
{Factor}: 3.838
{DOI}: 10.1002/pbc.31132
{Abstract}: Hepatoblastoma (HB) is a rare liver tumour, and its congenital counterpart (CHB) is even less frequent. CHB has a clinically challenging management and a generally perceived worse outcome. This study aims to review the literature on CHB to better define presentation, diagnosis, available treatments and management options. The analysis of outcomes suggests that a significant portion of mortality is unrelated to the malignant nature of the tumour. Key factors influencing overall outcomes were identified: mortality linked to the 'mass effect' during both the prenatal (22%) and perinatal (32%) stages, as well as 'oncological' mortality encompassing tumour and/or treatment-related factors (46%). Overall, after birth, CHB does not seem to confer a worse oncological prognosis per se, and should be managed similarly to older children, if patients are stable enough to undergo proper staging and treatment. A deeper knowledge and better outcomes would come from a large, homogeneous, collection of data possibly allowing a global protocol, focusing on a comprehensive management of CHB.